2. Academic Validation
  3. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease

The antibody aducanumab reduces Aβ plaques in Alzheimer's disease

  • Nature. 2016 Sep 1;537(7618):50-6. doi: 10.1038/nature19323.
Jeff Sevigny 1,  Ping Chiao 1,  Thierry Bussière 1,  Paul H Weinreb 1,  Leslie Williams 1,  Marcel Maier 2,  Robert Dunstan 1,  Stephen Salloway 3,  Tianle Chen 1,  Yan Ling 1,  John O'Gorman 1,  Fang Qian 1,  Mahin Arastu 1,  Mingwei Li 1,  Sowmya Chollate 1,  Melanie S Brennan 1,  Omar Quintero-Monzon 1,  Robert H Scannevin 1,  H Moore Arnold 1,  Thomas Engber 1,  Kenneth Rhodes 1,  James Ferrero 1,  Yaming Hang 1,  Alvydas Mikulskis 1,  Jan Grimm 2,  Christoph Hock 2 4,  Roger M Nitsch 2 4,  Alfred Sandrock 1
Affiliations

Affiliations

  • 1 Biogen, Cambridge, Massachusetts 02142, USA.
  • 2 Neurimmune, Schlieren-Zurich 8952, Switzerland.
  • 3 Butler Hospital, Providence, Rhode Island 02906, USA.
  • 4 Institute for Regenerative Medicine, University of Zurich, Zurich 8952, Switzerland.
PMID: 27582220 DOI: 10.1038/nature19323
Abstract

Alzheimer's disease (AD) is characterized by deposition of Amyloid-β (Aβ) plaques and neurofibrillary tangles in the brain, accompanied by synaptic dysfunction and neurodegeneration. Antibody-based immunotherapy against Aβ to trigger its clearance or mitigate its neurotoxicity has so far been unsuccessful. Here we report the generation of aducanumab, a human monoclonal antibody that selectively targets aggregated Aβ. In a transgenic mouse model of AD, aducanumab is shown to enter the brain, bind parenchymal Aβ, and reduce soluble and insoluble Aβ in a dose-dependent manner. In patients with prodromal or mild AD, one year of monthly intravenous infusions of aducanumab reduces brain Aβ in a dose- and time-dependent manner. This is accompanied by a slowing of clinical decline measured by Clinical Dementia Rating-Sum of Boxes and Mini Mental State Examination scores. The main safety and tolerability findings are amyloid-related imaging abnormalities. These results justify further development of aducanumab for the treatment of AD. Should the slowing of clinical decline be confirmed in ongoing phase 3 clinical trials, it would provide compelling support for the amyloid hypothesis.

Figures
Products